Donglin Sun

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Signaling Pathway

Top Venues

Oxidative medicine and cellular longevity

Cell death & disease

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Xiangqiu Chen, Li Wang
Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways. Oxidative medicine and cellular longevity 2023 (2023)
Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Xiangqiu Chen, Li Wang
Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways. Oxidative medicine and cellular longevity 2023 (2023)
Zhun Sun, Anning Chen, Hongwei Fang, Donglin Sun, Meiying Huang, Erdeng Cheng, Mengyuan Luo, Xiaoren Zhang, Hao Fang, Guojun Qian
B cell-derived IL-10 promotes the resolution of lipopolysaccharide-induced acute lung injury. Cell death & disease 14 (7) (2023)
Donglin Sun, Ningxia Xie, Xi Wang, Wenquan Wu, Xiu-Yong Li, Xiangqiu Chen, Guojun Qian, Cuifeng Li, Haohao Zhang, Yuhang Jiang, Deji Ye, Dandan Liu, Yiming Hu, Jingyao Wang, Weifeng Chen, Qiumei Zhao, Min Zeng, Junwei Zhang, Li Wang, Xiaoren Zhang
Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression. Clinical and translational medicine 11 (5) (2022)